FDA Guides Industry on New Drug Exclusivity Perks
Published Date: 3/4/2026
Notice
Summary
The FDA just dropped a draft guide to help drug makers understand how to get 3-year exclusivity for new clinical studies on their drugs. This means companies can protect their new research from competition for three years, encouraging innovation. If you’re in the drug business, get your comments in by May 4, 2026, or risk missing out on shaping the final rules!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
3‑year exclusivity blocks certain approvals
Under the cited statutory provisions (Hatch‑Waxman/section 505), a granted 3‑year New Clinical Investigation exclusivity means that 505(b)(2) applications and abbreviated new drug applications (505(j)/ANDAs) may not be approved for the exclusivity‑protected conditions of approval for three years after approval.
Draft guide explains 3‑year exclusivity
The FDA published a draft guidance titled “New Clinical Investigation Exclusivity (3‑Year Exclusivity) for Drug Products: Questions and Answers” to help applicants request 3‑year exclusivity under 21 U.S.C. 355(c)(3)(E)(iii)-(iv) and 355(j)(5)(F)(iii)-(iv). The guidance explains the statutory and regulatory eligibility criteria, how FDA will make eligibility determinations, recommends content/format in a Q&A style, and invites comments by May 4, 2026.
Template provided with no extra paperwork
The draft guidance includes a model template (in the Appendix) that FDA recommends applicants use to request New Clinical Investigation (3‑year) exclusivity. FDA tentatively concludes that providing the template “adds no further information collection requirements and imposes no further burden” beyond existing requirements covered by OMB control number 0910-0001.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16943, International Association of Color Manufacturers; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by the International Association of Color Manufacturers, proposing that we amend our color additive regulations to provide for the safe use of acetone as a solvent in the manufacture of carrot oil. The petition also proposes to add heavy metal limits and secondary names for carrot oil. FDA may also consider other changes to the regulation, as appropriate, during the course of our review.
Previous / Next Documents
Previous: 2026-04290, Proposed Collection; Comment Request
The Pentagon Force Protection Agency wants your thoughts on a new info collection about Pentagon access and visitor management. If you deal with Pentagon entry or visits, this could affect you. They’re asking for comments by May 4, 2026, to make sure the process is clear, useful, and not a hassle—no extra costs expected.
Next: 2026-04292, Proposed Collection; Comment Request
The Pentagon Force Protection Agency wants your thoughts on updating some forms they use to recruit and check the health and fitness of their team. If you’re involved or interested, you can comment until May 4, 2026. This update aims to make the forms clearer and easier to fill out, with no extra costs expected.